Issue 1/2017
Content (12 Articles)
Number Needed to Treat in Multiple Sclerosis Clinical Trials
Macaulay Okwuokenye, Annie Zhang, Amy Pace, Karl E. Peace
Informal Care Time and Cost in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer’s Disease: Determinants and Level of Change Observed
Loretto Lacey, Joel Bobula, Timothy Niecko, Christopher Leibman
Prescription Patterns of Medications for Alzheimer’s Disease in Japan from 2010 to 2015: A Descriptive Pharmacy Claims Database Study
Kimiko Kadohara, Izumi Sato, Yuko Doi, Masaru Arai, Yosuke Fujii, Toshiyuki Matsunaga, Koji Kawakami
Safety and Efficacy of Natalizumab in Japanese Patients with Relapsing-Remitting Multiple Sclerosis: Open-Label Extension Study of a Phase 2 Trial
Takahiko Saida, Jun-Ichi Kira, Shuji Kishida, Takashi Yamamura, Nobuhisa Ohtsuka, Yan Ling, Shinichi Torii, Nisha Lucas, Geoffrey Kuesters, Deb Steiner, J. T. Tibung
Risk of Adverse Outcomes for Older People with Dementia Prescribed Antipsychotic Medication: A Population Based e-Cohort Study
Michael Dennis, Laura Shine, Ann John, Amanda Marchant, Joanna McGregor, Ronan A. Lyons, Sinead Brophy
Quantifying the Benefits of Dimethyl Fumarate Over β Interferon and Glatiramer Acetate Therapies on Work Productivity Outcomes in MS Patients
Andrew Lee, James Pike, Michael R. Edwards, Jennifer Petrillo, John Waller, Eddie Jones
Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database
Aaron Boster, Jacqueline Nicholas, Ning Wu, Wei-Shi Yeh, Monica Fay, Michael Edwards, Ming-Yi Huang, Andrew Lee
Depression Among HIV/AIDS Patients on Highly Active Antiretroviral Therapy in the Southwest Regional Hospitals of Cameroon: A Cross-Sectional Study
Pleasure Atoh Ngum, Peter Nde Fon, Roland Cheofor Ngu, Vincent Siysi Verla, Henri Namme Luma
Treatment Patterns among Children and Adolescents with Attention-Deficit/Hyperactivity Disorder with or without Psychiatric or Neurologic Comorbidities in Sweden: A Retrospective Cohort Study
Vanja Sikirica, Per A. Gustafsson, Charles Makin
A Real-world Analysis of Treatment Patterns for Cholinesterase Inhibitors and Memantine among Newly-diagnosed Alzheimer’s Disease Patients
Nawal Bent-Ennakhil, Florence Coste, Lin Xie, Myrlene Sanon Aigbogun, Yuexi Wang, Furaha Kariburyo, Ann Hartry, Onur Baser, Peter Neumann, Howard Fillit
High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study
Simona Malucchi, Marco Capobianco, Marianna Lo Re, Maria Malentacchi, Alessia di Sapio, Manuela Matta, Francesca Sperli, Antonio Bertolotto
Natalizumab for Achieving Relapse-Free, T1 Gadolinium-Enhancing-Lesion-Free, and T2 Lesion-Free Status in Japanese Multiple Sclerosis Patients: A Phase 2 Trial Subanalysis
Takahiko Saida, Jun-Ichi Kira, Shuji Kishida, Takashi Yamamura, Nobuhisa Ohtsuka, Qunming Dong, J. T. Tibung